Browse News
Filter News
Found 21,754 articles
-
Nearly eight months after leaving his post as head of R&D at Johnson & Johnson, Mathai Mammen has found a new job as CEO of cancer focused FogPharma.
-
BioSpace Layoff Tracker 2023: Alector, Applied Molecular Transport, Satsuma and More Cut Staff
3/30/2023
Follow along as BioSpace keeps you up-to-date on which companies are tightening their belts and cutting staff throughout 2023. -
Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
3/30/2023
Zevra Therapeutics announced that it has appointed Wendy L. Dixon, Ph.D., to the Company’s Board of Directors, effective immediately following the conclusion of the 2023 Annual Meeting of Stockholders, to fill the vacancy resulting from Dr. Travis Mickle’s resignation from the Board effective as of the day of the 2023 Annual Meeting to be held on April 25, 2023.
-
PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023
3/30/2023
PDS Biotechnology Corporation (Nasdaq: PDSB) announced that it has completed key tech transfer, scale up and manufacturing activities required to initiate a global, multicenter Phase 3 registrational trial investigating the combination of PDS0101 and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in the fourth quarter of 2023.
-
Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study
3/30/2023
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced updated data from its Phase 1/2 ABILITY study of MDNA11, a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells.
-
AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise
3/30/2023
AIM ImmunoTech Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — announced Nancy K. Bryan as the newest member of its Board of Directors.
-
Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
3/30/2023
Merck, known as MSD outside of the United States and Canada, will hold its first-quarter 2023 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 27.
-
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2022
3/30/2023
Poolbeg Pharma Plc a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, is pleased to announce its audited results for the year ended 31 December 2022.
-
Mathai Mammen, M.D., Ph.D., to Join FogPharma as Chairman, President and Chief Executive Officer
3/30/2023
FogPharma®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and challenging intracellular targets, announced that Mathai Mammen, M.D., Ph.D., will join the company as chairman, president and chief executive officer.
-
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
3/30/2023
Icosavax, Inc. (Nasdaq: ICVX) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
-
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
3/30/2023
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2022, its recent business highlights, and a preview of select anticipated milestones.
-
OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
3/30/2023
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates.
-
Debbie's Dream Foundation Hosts More Than 130 Advocates at the 11th Annual Stomach Cancer Capitol Hill Advocacy Day
3/29/2023
Debbie's Dream Foundation: Curing Stomach Cancer successfully returned to Washington, DC, for the 11th Annual Stomach Cancer Capitol Hill Advocacy Day.
-
Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs
3/29/2023
Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities.
-
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
3/29/2023
Merck (NYSE: MRK) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to KEYTRUDA, Merck’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
-
Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer
3/29/2023
Lucy Therapeutics, Inc. today announced the appointment of Christopher J. Winrow, Ph.D., a neuroscience and translational medicine expert, as Chief Scientific Officer.
-
Merck’s Keytruda appeared to outperform GSK’s Jemperli in a key endometrial cancer patient subgroup, based on late-stage data revealed Monday during the Society of Gynecologic Oncology 2023 Annual Meeting.
-
Michael J. Fox Foundation for Parkinson's Research Announces Promising Results, Next Steps for "Ken Griffin Alpha-synuclein Imaging Competition"
3/28/2023
The Michael J. Fox Foundation for Parkinson's Research announced the culmination of the "Ken Griffin Alpha-synuclein Imaging Competition," a $10-million program launched in 2019 in pursuit of an imaging tracer to visualize the key protein alpha-synuclein in the living brains of people with Parkinson's disease.
-
Codagenix Announces Appointment of Kimber Poffenberger, Ph.D., as Chief Strategy Officer
3/28/2023
Codagenix Inc. today announced that Kimber Poffenberger, Ph.D., has been appointed Chief Strategy Officer.
-
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
3/28/2023
Immuneering Corporation, a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced that it has appointed Harold E. Brakewood as its Chief Business Officer.